Visual and anatomical outcomes of non-arteritic anterior ischemic optic neuropathy with high-dose systemic corticosteroids

Abstract

High-dose systemic steroid treatment did not show any beneficial effect in visual and anatomic outcomes when given during the acute phase of NAION. Furthermore, it caused serious complications in a third of the patients treated.

Changes in macular layers in the early course of non-arteritic ischaemic optic neuropathy

“…In previous interventional studies, patients were enrolled and treatment given to them if presentation was up to 2 weeks [14,20,21]. Since macular changes are already demonstrable at baseline and RGC death is already present at 2 weeks [18], it would be critical to administer any putative treatment as early as possible (hours from onset) and whilst documenting the state of the macula.…”

Three episodes of non-arteritic posterior ischemic optic neuropathy in the same patient treated with intravenous prostaglandin E1

“…Steroid therapy is, however, not universally accepted. A more recent study using high-dose systemic steroids to treat acute NAION noted no visual or anatomic benefit and several serious complications from steroids (11). However, steroids were used in the current case for another reason, i.e.…”

Visual field improvement in non-arteritic posterior ischemic optic neuropathy in a patient treated with intravenous prostaglandin E1 and steroids

“…Steroid therapy is, however, not universally accepted. A more recent study using high-dose systemic steroid treatment in acute NA-AION noted no visual or anatomic benefit and some serious complications due to steroids (13). However, the current authors used steroids for another reason: to try to reduce ischemia-reperfusion injury.…”